CD206

ROCKVILLE, Md., Dec. 12, 2024 /PRNewswire/ -- The Association of Cancer Care Centers (ACCC) is proud to announce an innovative quality improvement (QI) workshop opportunity designed to help cancer centers integrate biomarker testing into treatment plans for patients with gynecologic cancers. Why Biomarker Testing Matters Biomarker testing has proven an essential tool for diagnosis and treatment for gynecologic cancers. Despite its critical importance, barriers such as financial challenges, care coordination gaps, and limited provider awareness prevent many patients from accessing testing. Customized Workshop Opportunity This initiative offers cancer centers an opportunity to lead the way in improving access to biomarker testing, ultimately advancing the quality of care for patients with gynecologic cancers. ACCC is inviting cancer centers to participate in a QI initiative aimed at: Assessing Gaps: Identifying barriers to implementing guideline-concordant testing for biomarkers such as HRD, MMR/MSI, and HER2 Addressing Barriers: Tackling social drivers of health (SDOH) such as financial toxicity, coordination of genetic testing, and provider education Enhancing Care: Developing actionable strategies and accessing resources to integrate biomarker testing. Selected sites will also receive a $10,000 stipend to support their participation in this program. Additionally, participants will gain hands-on access to resources such as ACCC's Quality Self-Assessment Tool for Ovarian Cancer Care Delivery. Inspired by the research of Temkin et al., this resource helps cancer programs: Conduct baseline assessments of care practices Identify gaps across 7 key domains, including prevention, care coordination, and survivorship Implement evidence-based strategies to elevate the quality of gynecologic cancer care. Get Involved Centers interested in participating in this workshop and QI initiative are encouraged to contact Bianca Alvarez, MPH, CHES, at [email protected]. This QI initiative and the assessment tool underscore ACCC's commitment to supporting cancer programs in delivering equitable, patient-centered care that addresses the unique challenges of gynecologic cancer treatment. About ACCC The Association of Cancer Care Centers (ACCC) is the leading education and advocacy organization for the cancer care community. With a network of more than 45,000 multidisciplinary professionals, ACCC is dedicated to improving access, quality, and equity in cancer care delivery. SOURCE Association of Cancer Care Centers (ACCC) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

NEW YORK--( BUSINESS WIRE )--PIF Partners announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its proprietary investigational therapeutic 101-PGC-005 (‘005) for the treatment of systemic juvenile idiopathic arthritis (sJIA) flares. ‘005 is a Type IA prodrug of dexamethasone that targets CD206 + macrophages. Currently, ‘005 is in Phase 3 clinical trials in 9 centers in India for the treatment of ARDS induced by COVID-19, registered under CTRI/2024/01/061531. “We are thrilled the FDA has recognized the potential of ‘005 to address the significant unmet medical needs of children suffering from sJIA,” said Alec Goldberg, CEO of PIF Partners. “This designation is a pivotal milestone that reinforces our commitment to developing innovative therapies for rare pediatric inflammatory diseases. By targeting activated macrophages with the most powerful anti-inflammatory compounds, we enhance efficacy and reduce toxicity. Critically, we have demonstrated no suppression of the HPA system, thus supplementing rather than replacing the natural anti-inflammatory response. We are eager to advance our clinical program and expand our research into other orphan diseases characterized by systemic inflammation.” The FDA awards RPDDs to promote the development of new drugs and biologics for serious or life-threatening diseases that primarily affect children under 18 years old and impact fewer than 200,000 people in the United States. This designation makes PIF Partners eligible to receive a Priority Review Voucher (PRV) upon approval of ‘005. A PRV can be redeemed to obtain priority review for a subsequent marketing application, accelerating the review process from the standard 10 months to six months. About sJIA sJIA is a rare and severe autoinflammatory disease affecting children under 16. Unlike other forms of juvenile arthritis, sJIA is characterized by systemic symptoms such as high spiking fevers, rash, enlargement of the liver and spleen, and inflammation of the lining of the heart and lungs (serositis), in addition to persistent joint inflammation. sJIA accounts for approximately 10-20% of all cases of juvenile idiopathic arthritis. The disease poses significant challenges, including chronic pain, growth retardation, joint damage, and potential life-threatening complications like macrophage activation syndrome (MAS). Current treatment options are limited and often involve long-term use of corticosteroids and immunosuppressive drugs, which can have serious side effects. There is a pressing need for new therapies that can effectively manage both the systemic and joint-related symptoms with improved safety profiles. About PIF Partners PIF Partners is a holding company with exclusive rights to ‘005 and other therapeutics using the underlying macrophage targeting platform. The company is seeking a partner to rapidly progress the development and commercialization of novel therapies for systemic juvenile idiopathic arthritis (sJIA) and other rare diseases characterized by systemic inflammation. Focused on addressing critical gaps in treatment, the company is advancing a pipeline of exclusively licensed therapeutic candidates targeting CD206 + macrophages. For more information, please visit pifpartners.com.

Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON, May 22, 2024 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round. The additional investment from Bristol Myers Squibb will enable NeoPhore to explore novel biology associated with the DNA mismatch repair ('MMR') pathway in cancer, as well as further progress its pre-clinical studies and deliver a candidate drug in 2025. NeoPhore is focused on building a pipeline of small molecule drugs targeting novel proteins across the MMR pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. Its first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy. Dr Matthew Baker, Chief Executive Officer of NeoPhore, said: "We are thrilled to have Bristol Myers Squibb, an innovator in the immuno-oncology space, join our oversubscribed Series B extension round. The funding strengthens NeoPhore's position and enables us to complete the necessary pre-clinical studies to deliver a candidate drug for our lead PMS2 program in 2025." Dr Robert James, Chairman of NeoPhore, said: "The addition of Bristol Myers Squibb to the Series B extension supports NeoPhore's novel approach to targeting the MMR pathway with small molecule inhibitors to treat cancer. Building on NeoPhore's successes in 2023, we hope to see a year of progress for the Company's pre-clinical programs". NOTES TO EDITORS About NeoPhore Ltd NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients' immune system to overcome natural defence mechanisms in cancer. The Company's approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund. For more information, please visit About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. SOURCE NeoPhore